Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Inclusion Criteria:

1. Able to understand and willing to comply with all study requirements and proceduresthroughout the duration of the study and give written informed consent;
2. Aged ≥18 years;
3. Patients receiving moderate- or high-intensity statin therapy must meet one of thefollowing criteria¹ unless they have any exceptional conditions (see inclusioncriterion 4):
4. Aged ≥21 years with clinical atherosclerotic cardiovascular disease (ASCVD) (history of acute coronary syndrome or myocardial infarction, stable or unstableangina, coronary or other arterial revascularization, stroke, transient ischemicattack [TIA] presumed to be of atherosclerotic origin, or peripheral arterialdisease or revascularization), on a high-intensity statin (or moderate-intensitystatin if not a candidate for high-intensity statin due to safety concerns);
5. Aged ≥21 years with a history of LDL-C ≥190 mg/dL, which is not due to secondarymodifiable causes, on a high-intensity statin (or moderate-intensity statin ifnot a candidate for high-intensity statin due to safety concerns);
6. Aged 40 to 75 years, inclusive, without clinical ASCVD but with diabetes and ahistory of LDL-C of 70 to 189 mg/dL, inclusive, on a moderate- or high-intensitystatin; or
7. Aged 40 to 75 years, inclusive, without clinical ASCVD or diabetes, with ahistory of LDL-C of 70 to 189 mg/dL, inclusive, with estimated 10-year risk forASCVD of ≥7.5% by the Pooled Cohort Equation on a moderate- or high-intensitystatin;
8. Patients currently on a low-intensity statin or not on a statin, must meet one of thefollowing criteria;
9. Patient does not meet any criteria for moderate- or high-intensity statin therapylisted above (see inclusion criteria, 3.a. through 3.d.);
10. Patient does meet one or more criteria for moderate- or high-intensity statintherapy listed above (see inclusion criteria 3.a. through 3.d.); but the patientis not a candidate for moderate or high-intensity statin due to safety concerns,or due to partial or complete statin intolerance; or
11. Patient does meet one or more criteria for moderate- or high intensity statintherapy listed above (see inclusion criteria 3.b. through 3.d., except for 3.a.);but the patient is not a candidate for moderate or high intensity statin forprimary prevention after considering individual risk evaluation (e.g. current LDLC ≤70mg/dL) and patient preference;
12. Fasting TG levels ≥500 mg/dL (5.65 mmol/L) and <2000 mg/dL (22.60 mmol/L) based on themean of Visit 2 (Week -2) and Visit 3 (Week -1).

• Mild to moderate renal impairment eGFR >= 30mL/min/1.73 and < 90 mL/min/1.73 atVisit 1

Exclusion Criteria:

1. Patients who will require lipid-altering treatments other than study drugs (K-877 orfenofibrate), statins, ezetimibe, or PCSK9 inhibitors during the course of the study.These include bile acid sequestrants, non-study fibrates, niacin (>100 mg/day),omega-3 fatty acids (>1000 mg/day), or any supplements used to alter lipid metabolismincluding, but not limited to, red rice yeast supplements, garlic supplements, soyisoflavone supplements, sterol/stanol products, or policosanols;
2. Body mass index (BMI) >45 kg/m2 at Visit 1 (Week -8 or Week -6);
3. Patients with type 1 diabetes mellitus;
4. Patients with newly diagnosed (within 3 months prior to Visit 2 [Week -2]) or poorlycontrolled type 2 diabetes mellitus (T2DM), defined as hemoglobin A1c >9.5% at Visit 1 (Week -8 or Week -6);